NEW YORK (TheStreet) -- ImClone founder Samuel Waksal is raising money, hoping to launch a biopharmaceutical start-up. But it wasn't so long ago that the biotech entrepreneur was serving seven years behind bars for a series of white collar crimes that also enmeshed friend and domestic doyenne Martha Stewart.A quick recap: After receiving a tip in December 2001 that the U.S. Food and Drug Administration would reject the application for Erbitux, a colon cancer drug, Waksal tried to sell 80,000 of the company's shares. The day before the FDA's rejection, Waksal's family, close friends, and other big ImClone shareholders -- including Stewart -- sold millions worth of stock. The stock then started to tank, falling into the teens after its December high of around $60. Six months later, Waksal was arrested on charges that he illegally acted on inside information in attempting to sell ImClone shares -- and that he tipped family members to do the same. A host of other charges followed, including bank fraud, obstruction of justice, and even tax evasion on $15 million worth of art. Here, in pictures, is a brief timeline of Waksal and Co.'s less-than-finer moments with ImClone.
June 13, 2002
A day after being arrested on charges he illegally acted on insider information about selling shares of his company's stock, Waksal is sworn in on Capitol Hill, where he testified before a House Commerce subcommittee hearing. During the hearing, Waksal invoked his Fifth Amendment right against self-incrimination and refused to answer questions that examined a case that wound up costing investors millions and disappointed dying cancer patients.
Oct. 10, 2002
Harlan Waksal, Samuel Waksal's brother and co-founder of the company, eventually took over as the company's chief before resigning in July 2003. Here he testifies before a U.S. House subcommittee, which released documents showing that officers and directors of ImClone sold $70.3 million of their company stock in December, just weeks before it plunged on news that the government rejected ImClone's application for Erbitux.
July 16, 2004
March 4, 2005
About three years after Waksal was convicted of insider trading, activist investor Carl Icahn acquired the majority of ImClone's stock and took control of the company's board. Icahn and his pack ran the company for about two years, until overseeing its sale to drug giant Eli Lilly ( LLY).
Oct. 6, 2008
Looking to broaden its pipeline of cancer treatments, biotech firm Eli Lilly acquired ImClone for about $6.5 billion -- a deal that priced ImClone stock at $70 per share. Lilly beat out rival Bristol-Myers Squibb ( BMY), which held a partnership to market ImClone's flagship cancer drug, Erbitux, in the U.S. Pfizer ( PFE) also reportedly entertained a bid at one time. Bristol-Meyers, which helped ImClone develop the cancer drug, bid first, offering $62 a share. Today, both firms market the drug.